Home Tags CD22+

Tag: CD22+

Featured Image: Doctor explaining diagnosis to her patient Courtesy: © 2017 Fotolia. Used with permission.

Triphase’s TRPH-222, a Site-specific Anti-CD22 ADC, Enters Clinical Phase I Trials

Triphase Accelerator, a company dedicated to acquiring and developing novel therapeutics for the treatment of cancer, and Catalent, the leading global provider of advanced...

New Licensing Agreement Is Expected to Advance Catalent’s Proprietary SMARTag Technology...

This week, during the annual CPhI World Wide congress and exhibition being held in Barcelona, Spain, June 4 - 6, 2016, Catalent, the leading...

University of Minnesota Masonic Cancer Center Proceeds With Development Novel Leukemia...

Scientists at the University of Minnesota Masonic Cancer Center have received notification from the U.S. Food and Drug Administration (FDA) that they can proceed...

Novel Anti-CD22 Antibody-Drug Conjugate Shows Positive Pre-clinical Activity

The 106th Annual Meeting of the American Association for Cancer Research (AACR) being held April 18-22, 2015 in Philadelphia, PA, included a poster presentation...

Clinical Trial with Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin...

Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the...